Supernus Pharmaceuticals, Inc.

NasdaqGM:SUPN Stok Raporu

Piyasa değeri: US$1.8b

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Supernus Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Supernus Pharmaceuticals' CEO'su Jack Khattar, Jan2005 tarihinde atandı, in görev süresi 19.75 yıldır. in toplam yıllık tazminatı $ 13.28M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.3% maaş ve 92.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 3.54% ine doğrudan sahiptir ve bu hisseler $ 60.76M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 9.5 yıl ve 14.8 yıldır.

Anahtar bilgiler

Jack Khattar

İcra Kurulu Başkanı

US$13.3m

Toplam tazminat

CEO maaş yüzdesi7.3%
CEO görev süresi19.8yrs
CEO sahipliği3.5%
Yönetim ortalama görev süresi9.5yrs
Yönetim Kurulu ortalama görev süresi14.8yrs

Son yönetim güncellemeleri

Recent updates

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Sep 12

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Aug 19
Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

Jul 02

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Mar 04

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

May 10
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Feb 03
Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19
These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Oct 10

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Aug 19

Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Aug 16
Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Supernus: A Work In Progress

Jul 29

Supernus: New Beginnings

Mar 28

Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Dec 02
Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Nov 30
Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

Oct 19
Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

CEO Tazminat Analizi

Jack Khattar'un ücretlendirmesi Supernus Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

US$5m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$13mUS$963k

US$1m

Sep 30 2023n/an/a

US$26m

Jun 30 2023n/an/a

US$43m

Mar 31 2023n/an/a

US$52m

Dec 31 2022US$10mUS$914k

US$61m

Sep 30 2022n/an/a

US$38m

Jun 30 2022n/an/a

US$57m

Mar 31 2022n/an/a

US$73m

Dec 31 2021US$8mUS$870k

US$53m

Sep 30 2021n/an/a

US$82m

Jun 30 2021n/an/a

US$100m

Mar 31 2021n/an/a

US$111m

Dec 31 2020US$7mUS$836k

US$127m

Sep 30 2020n/an/a

US$129m

Jun 30 2020n/an/a

US$118m

Mar 31 2020n/an/a

US$116m

Dec 31 2019US$8mUS$812k

US$113m

Sep 30 2019n/an/a

US$106m

Jun 30 2019n/an/a

US$105m

Mar 31 2019n/an/a

US$103m

Dec 31 2018US$7mUS$724k

US$111m

Sep 30 2018n/an/a

US$99m

Jun 30 2018n/an/a

US$87m

Mar 31 2018n/an/a

US$73m

Dec 31 2017US$6mUS$614k

US$57m

Tazminat ve Piyasa: Jack 'nin toplam tazminatı ($USD 13.28M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.54M ).

Tazminat ve Kazançlar: Jack şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.

CEO

Jack Khattar (63 yo)

19.8yrs

Görev süresi

US$13,278,093

Tazminat

Mr. Jack A. Khattar, M.B.A., founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as Chief Executive Officer, President, Secretary and Director since 2005. He...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Jack Khattar
Founder19.8yrsUS$13.28m3.54%
$ 62.5m
Timothy Dec
Senior VP & CFO3.2yrsUS$2.38m0.013%
$ 230.6k
Padmanabh Bhatt
Chief Scientific Officer & Senior VP of Intellectual Property12.6yrsUS$1.47m0.018%
$ 310.2k
Frank Mottola
Senior Vice President of Quality4.8yrsUS$1.79m0.014%
$ 249.5k
Jonathan Rubin
Senior VP of Research & Development and Chief Medical Officer4.7yrsUS$1.59m0.0084%
$ 148.8k
Kevin Anderson
Compliance Officer12.8yrsVeri yokVeri yok
Todd Horich
Senior Vice President of Marketing9.8yrsVeri yokVeri yok
Taylor Raiford
Senior Vice President of Sales9.8yrsVeri yokVeri yok
Bryan Roecklein
Senior Vice President of Corporate Development9.3yrsVeri yokVeri yok
Jeff Bozick
Senior Vice President of Supply Chain3.4yrsVeri yokVeri yok

9.5yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim: SUPN 'un yönetim ekibi deneyimli ve deneyimlidir ( 9.5 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Jack Khattar
Founder19.8yrsUS$13.28m3.54%
$ 62.5m
Charles Newhall
Independent Chairman of the Board19.8yrsUS$407.02k0.22%
$ 3.9m
Georges Gemayel
Independent Director9.6yrsUS$378.52k0.024%
$ 426.8k
Carrolee Barlow
Independent Director6.3yrsUS$376.02k0.031%
$ 551.4k
Frederick Hudson
Independent Director14.8yrsUS$385.02k0.067%
$ 1.2m

14.8yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SUPN 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 14.8 yıldır).